A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma
American Journal of Hematology · 2026-09 · 101 (9) · 2177-2189
DOI: 10.1002/ajh.70403 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 12.06.2026. Verfasst von Julio C Chavez und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Rituximab, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: F. Hoffmann-La Roche Ltd.
Abstract (Originalsprache)
Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with > 2 years of follow‐up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun‐Pola or R‐Pola. Mosunetuzumab was administered subcutaneously with Cycle (C) 1 step‐up dosing (5/45/45 mg) then 45 mg on C2 Day (D) 1–C8D1 (21‐day cycles). Polatuzumab vedotin (1.8 mg/kg) was given intravenously (IV) on D1 of C1–6. Rituximab IV (375 mg/m 2 ) was given on D1 of C1–8. Primary endpoint was best objective response rate (ORR). As of November 15, 2024, 80 patients had been enrolled (Mosun‐Pola, n = 40; R‐Pola, n = 40). Best ORR was 77.5% (95% confidence interval [CI] 61.6–89.2) for Mosun‐Pola and 50.0% (95% CI: 33.8–66.2) for R‐Pola; complete response (CR) rates were 55.0% (95% CI: 38.5–70.7) and 35.0% (95% CI: 20.6–51.7), respectively. Median progression‐free survival was 25.4 months for Mosun‐Pola and 6.4 months for R‐Pola (hazard ratio [HR] 0.47); median overall survival was not reached and 25.5 months (HR: 0.78), respectively. Cytokine release syndrome occurred in 12.5% of Mosun‐Pola‐treated patients (all Grade 1/2). Fixed‐duration Mosun‐Pola demonstrated benefit across all efficacy endpoints compared with R‐Pola in patients with R/R LBCL. These findings are consistent with the observed benefit of Mosun‐Pola for patients with R/R LBCL in the global Phase III SUNMO study (NCT05171647). Trial Registration: Clinicaltrials.gov number: NCT03671018
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health, New York, New York, USA.
- Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida, USA.
- Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Division of Hematology, Jewish General Hospital, Montreal, Quebec, Canada.
ORCID-Profile: Julio C Chavez, Izidore S Lossos, Nirav Shah, Seema Naik, Nilanjan Ghosh
Förderung
- F. Hoffmann-La Roche Ltd
Zitieren
APA
Chavez, J. C., Bastos-Oreiro, M., Diefenbach, C., Lossos, I. S., Shah, N., Assouline, S., Olszewski, A. J., Naik, S., Ghosh, N., Pham, S., Wei, M. C., Batlevi, C., To, I., Ead, W., Makadia, S., Penuel, E., Jing, J., & Budde, L. E. (2026). A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma. American Journal of Hematology, 101(9), 2177-2189. https://doi.org/10.1002/ajh.70403
Vancouver
Chavez JC, Bastos-Oreiro M, Diefenbach C, Lossos IS, Shah N, Assouline S, et al. A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma. American Journal of Hematology. 2026;101(9):2177-2189. doi:10.1002/ajh.70403
BibTeX
@article{Chavez2026,
author = {Chavez, Julio C and Bastos-Oreiro, Mariana and Diefenbach, Catherine and Lossos, Izidore S and Shah, Nirav and Assouline, Sarit and Olszewski, Adam J and Naik, Seema and Ghosh, Nilanjan and Pham, Song and Wei, Michael C and Batlevi, Connie and To, Iris and Ead, Wahib and Makadia, Sneha and Penuel, Elicia and Jing, Jing and Budde, Lihua E},
title = {A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {9},
pages = {2177--2189},
doi = {10.1002/ajh.70403}
}
EUVIMED